Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

Researchers show that JQ1 drug can block molecular pathway responsible for heart failure

Researchers from Case Western Reserve University School of Medicine and the Dana-Farber Cancer Institute have made a fundamental discovery relevant to the understanding and treatment of heart failure - a leading cause of death worldwide. The team discovered a new molecular pathway responsible for causing heart failure and showed that a first-in-class prototype drug, JQ1, blocks this pathway to protect the heart from damage.

2 Aug 2013

Fertility medications not linked with increased risk of CVD later in life

Women who gave birth following fertility treatment had no long-term increased risk of death or major cardiovascular events compared to women who gave birth without fertility therapy, according to new research by the Institute for Clinical Evaluative Sciences (ICES) and Women's College Hospital.

1 Aug 2013

HHS Inspector General raises concerns about Medicare policy on observation care

The report also finds that policies on admitting patients or keeping them under observation -- a distinction that can have dramatic financial impact on the patients -- varies substantially among hospitals.

31 Jul 2013

Inhalable gene therapy may restore function of crucial enzyme to reverse deadly PAH

The deadly condition known as pulmonary arterial hypertension (PAH), which afflicts up to 150,000 Americans each year, may be reversible by using an inhalable gene therapy, report an international team of researchers led by investigators at the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai.

31 Jul 2013

Researchers uncover genetics behind what makes some people susceptible to Takayasu arteritis

Researchers have uncovered the genetics behind what makes some people susceptible to Takayasu arteritis, a debilitating disease that can lead to poor circulation, easy tiredness in the legs and arms, organ damage and stroke.

30 Jul 2013

Gout, uric acid levels and risk of death: an interview with Professor Austin Stack, Graduate Entry Medical School, University of Limerick

Gout is a relatively common arthritic disease that affects about 4% (I in 25) of the population. It results from the deposition of uric acid in joints due to elevated blood levels and a resulting inflammation ensues which is very painful.

26 Jul 2013

Researchers explain how gut bacteria can inactivate cardiac drugs

For decades, doctors have understood that microbes in the human gut can influence how certain drugs work in the body - by either activating or inactivating specific compounds, but questions have long remained about exactly how the process works.

26 Jul 2013

Scientists identify new genetic mutations that can cause pulmonary arterial hypertension

Columbia University Medical Center (CUMC) scientists have identified new genetic mutations that can cause pulmonary arterial hypertension (PAH), a rare fatal disease characterized by high blood pressure in the lungs.

25 Jul 2013

MedUni Vienna cardiologist demonstrates effectiveness of substance that makes heart softer

Heart failure with concomitant pulmonary hypertension is a growing health problem with a high mortality rate, above all in older people. The cardiologist Diana Bonderman from the University Department of Internal Medicine II at the MedUni Vienna, as the author of a multinational phase II study, has demonstrated the effectiveness of a substance that sticks to the so-called nitric oxide pathway and makes the heart "softer".

19 Jul 2013

Study leads to new approach for treatment of aortic valve stenosis

A study conducted by the team of Dr. Jean-Claude Tardif, Director of the Research Centre at the Montreal Heart Institute, has led to the discovery of a new approach to treat aortic valve stenosis through the administration of a compound that prevents valve deterioration and can even reverse the progression of the disease.

19 Jul 2013

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

Janssen Biotech, Inc. announced today the U.S. Food and Drug Administration approval of SIMPONI ARIATM (golimumab) for infusion for the treatment of adults with moderately to severely active rheumatoid arthritis in combination with methotrexate.

19 Jul 2013

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Celgene Corporation today announced that after consultation with the U.S. Food and Drug Administration Celgene will discontinue treatment with REVLIMID (lenalidomide) in the open-label, phase III ORIGIN trial, which enrolled 450 patients in over 100 sites in 26 countries.

18 Jul 2013

Drug to treat multiple sclerosis may also hold promise for treating cardiac hypertrophy

A drug already approved to treat multiple sclerosis may also hold promise for treating cardiac hypertrophy, or thickening of the cardiac muscle--a disorder that often leads to heart failure, researchers at the University of Illinois at Chicago College of Medicine report.

17 Jul 2013

Insurance status affects spinal surgery outcomes

Among patients undergoing spinal surgery, Medicaid beneficiaries are at higher risk of experiencing any type of complication, compared to privately insured patients, reports a study in the July 15 issue of of Spine. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

16 Jul 2013

TSRI scientists design drug candidate that increases exercise endurance in animal models

An international group of scientists has shown that a drug candidate designed by scientists from the Florida campus of The Scripps Research Institute (TSRI) significantly increases exercise endurance in animal models.

15 Jul 2013

Alnylam releases positive top-line data from ALN-TTRsc Phase I trial for TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive top-line results from its ongoing Phase I trial of ALN-TTRsc, a subcutaneously administered RNAi therapeutic targeting the transthyretin gene for the treatment of TTR-mediated amyloidosis.

12 Jul 2013

State highlights: Disabled at risk at Calif. facilities, audit finds; Advocates push for single policy for kids' medical, dental coverage in exchange plans; Ga. maternal mortality

Californians with developmental disabilities who are cared for at state facilities are being put at risk by outdated policies and inadequate investigations of abuse, the state auditor's office said Tuesday. Allegations that residents have been raped, shot with stun guns and otherwise abused have not been acted on satisfactorily, auditors found. The California Department of Developmental Services cares for 1,480 severely disabled people in five facilities throughout the state (McGreevy, 7/9).

11 Jul 2013

Heart Failure News and Research

Further Reading

Researchers show that JQ1 drug can block molecular pathway responsible for heart failure

Fertility medications not linked with increased risk of CVD later in life

HHS Inspector General raises concerns about Medicare policy on observation care

Inhalable gene therapy may restore function of crucial enzyme to reverse deadly PAH

Researchers uncover genetics behind what makes some people susceptible to Takayasu arteritis

Gout, uric acid levels and risk of death: an interview with Professor Austin Stack, Graduate Entry Medical School, University of Limerick

Researchers explain how gut bacteria can inactivate cardiac drugs

Scientists identify new genetic mutations that can cause pulmonary arterial hypertension

MedUni Vienna cardiologist demonstrates effectiveness of substance that makes heart softer

Study leads to new approach for treatment of aortic valve stenosis

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Drug to treat multiple sclerosis may also hold promise for treating cardiac hypertrophy

Insurance status affects spinal surgery outcomes

TSRI scientists design drug candidate that increases exercise endurance in animal models

Alnylam releases positive top-line data from ALN-TTRsc Phase I trial for TTR-mediated amyloidosis

State highlights: Disabled at risk at Calif. facilities, audit finds; Advocates push for single policy for kids' medical, dental coverage in exchange plans; Ga. maternal mortality

Short-term exposure to air pollution increases risk of heart failure

Heart transplant could get a second chance to save life

First Edition: July 10, 2013

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News